Discovery of neddylation E2s inhibitors with therapeutic activity

被引:0
|
作者
MAA Mamun
Ying Liu
Yin-Ping Geng
Yi-Chao Zheng
Ya Gao
Jian-Gang Sun
Long-Fei Zhao
Li-Juan Zhao
Hong-Min Liu
机构
[1] Zhengzhou University,Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China; State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Dr
[2] the First Affiliated Hospital of Zhengzhou University,Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy; Department of Pharmacy
[3] the First Affiliated Hospital of Zhengzhou University,Department of Gastrointestinal Surgery
[4] Zhengzhou University,State Key Laboratory of Esophageal Cancer Prevention & Treatment, Academy of Medical Sciences
来源
Oncogenesis | / 12卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Neddylation is the writing of monomers or polymers of neural precursor cells expressed developmentally down-regulated 8 (NEDD8) to substrate. For neddylation to occur, three enzymes are required: activators (E1), conjugators (E2), and ligators (E3). However, the central role is played by the ubiquitin-conjugating enzymes E2M (UBE2M) and E2F (UBE2F), which are part of the E2 enzyme family. Recent understanding of the structure and mechanism of these two proteins provides insight into their physiological effects on apoptosis, cell cycle arrest and genome stability. To treat cancer, it is therefore appealing to develop novel inhibitors against UBE2M or UBE2F interactions with either E1 or E3. In this evaluation, we summarized the existing understanding of E2 interaction with E1 and E3 and reviewed the prospective of using neddylation E2 as a pharmacological target for evolving new anti-cancer remedies.
引用
收藏
相关论文
共 50 条
  • [1] Discovery of neddylation E2s inhibitors with therapeutic activity
    Mamun, M. A. A.
    Liu, Ying
    Geng, Yin-Ping
    Zheng, Yi-Chao
    Gao, Ya
    Sun, Jian-Gang
    Zhao, Long-Fei
    Zhao, Li-Juan
    Liu, Hong-Min
    ONCOGENESIS, 2023, 12 (01)
  • [2] Targeting neddylation E2s: a novel therapeutic strategy in cancer
    Zheng, Yi-Chao
    Guo, Yan-Jia
    Wang, Bo
    Wang, Chong
    Mamun, M. A. A.
    Gao, Ya
    Liu, Hong-Min
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [3] Targeting neddylation E2s: a novel therapeutic strategy in cancer
    Yi-Chao Zheng
    Yan-Jia Guo
    Bo Wang
    Chong Wang
    M. A. A. Mamun
    Ya Gao
    Hong-Min Liu
    Journal of Hematology & Oncology, 14
  • [4] The Functional Redundancy of Neddylation E2s and E3s in Modulating the Fitness of Regulatory T Cells
    Wu, Di
    Sun, Yi
    RESEARCH, 2023, 6
  • [5] Inhibiting E2s
    Mason S.
    Nature Structural & Molecular Biology, 2012, 19 (3) : 267 - 267
  • [6] Discovery of dual tubulin-NEDDylation inhibitors with antiproliferative activity
    Fu, Dong-Jun
    Wang, Ting
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) : 166 - 175
  • [7] E2s: structurally economical and functionally replete
    Wenzel, Dawn M.
    Stoll, Kate E.
    Klevit, Rachel E.
    BIOCHEMICAL JOURNAL, 2011, 433 : 31 - 42
  • [8] Investigation of a special neutralizing epitope of HEV E2s
    You, Min
    Xin, Lu
    Yang, Yi
    Zhang, Xiao
    Chen, Yingwei
    Yu, Hai
    Li, Shaowei
    Zhang, Jun
    An, Zhiqiang
    Luo, Wenxin
    Xia, Ningshao
    PROTEIN & CELL, 2014, 5 (12) : 950 - 953
  • [9] Cbl interacts with multiple E2s in vitro and in cells
    Liyasova, Mariya S.
    Ma, Ke
    Voeller, Donna
    Ryan, Philip E.
    Chen, Jinqiu
    Klevit, Rachel E.
    Lipkowitz, Stanley
    PLOS ONE, 2019, 14 (05):
  • [10] Investigation of a special neutralizing epitope of HEV E2s
    Min You
    Lu Xin
    Yi Yang
    Xiao Zhang
    Yingwei Chen
    Hai Yu
    Shaowei Li
    Jun Zhang
    Zhiqiang An
    Wenxin Luo
    Ningshao Xia
    Protein & Cell, 2014, 5 (12) : 950 - 964